Dmitry Zamansky Sells 5,575 Shares of American Well (NYSE:AMWL) Stock

American Well Corporation (NYSE:AMWL) insider Dmitry Zamansky sold 5,575 shares of the company’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $5.30, for a total transaction of $29,547.50. Following the completion of the sale, the insider directly owned 241,080 shares of the company’s stock, valued at $1,277,724. This represents a 2.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Dmitry Zamansky also recently made the following trade(s):

• On Friday, January 2nd, Dmitry Zamansky sold 6,243 shares of American Well stock. The stock was sold at an average price of $4.85, for a total transaction of $30,278.55.

American Well Stock Up 4.1%

NYSE:AMWL traded up $0.22 on Thursday, hitting $5.51. The stock had a trading volume of 22,215 shares, compared to its average volume of 92,324. The company has a fifty day moving average price of $5.20 and a two-hundred day moving average price of $5.09. American Well Corporation has a 1-year low of $3.71 and a 1-year high of $9.15. The stock has a market cap of $91.12 million, a price-to-earnings ratio of -0.93 and a beta of 1.34.

American Well (NYSE:AMWL) last announced its quarterly earnings results on Thursday, February 12th. The company reported ($1.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.59) by $0.07. American Well had a negative net margin of 38.38% and a negative return on equity of 35.33%. The business had revenue of $55.31 million during the quarter, compared to the consensus estimate of $52.71 million. As a group, analysts anticipate that American Well Corporation will post -9.34 earnings per share for the current year.

Hedge Funds Weigh In On American Well

Several institutional investors have recently bought and sold shares of AMWL. Headlands Technologies LLC purchased a new stake in American Well during the second quarter worth about $39,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of American Well in the third quarter valued at approximately $62,000. Occudo Quantitative Strategies LP purchased a new stake in American Well during the 4th quarter worth approximately $74,000. NewEdge Advisors LLC purchased a new stake in American Well during the 4th quarter worth approximately $82,000. Finally, Prelude Capital Management LLC acquired a new stake in American Well during the 3rd quarter worth approximately $86,000. 56.05% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

AMWL has been the topic of a number of recent analyst reports. Stifel Nicolaus decreased their target price on shares of American Well from $6.00 to $5.00 and set a “hold” rating on the stock in a research report on Friday, February 13th. Wall Street Zen raised shares of American Well from a “sell” rating to a “hold” rating in a research note on Sunday, March 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of American Well in a research report on Wednesday, January 21st. Finally, Morgan Stanley dropped their target price on shares of American Well from $10.50 to $6.00 and set an “equal weight” rating for the company in a report on Thursday, December 18th. One research analyst has rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $7.42.

American Well Company Profile

American Well, operating under the trade name Amwell, is a Boston-based digital health company that develops and delivers telehealth solutions to healthcare providers, payers, employers and patients. Through its cloud-based platform, the company enables secure virtual visits, remote patient monitoring and integrated care coordination across a range of medical disciplines, including primary care, behavioral health, chronic disease management and urgent care.

The company’s core offering, the Amwell Telehealth Platform, facilitates live video consultations, asynchronous messaging, e-prescribing and electronic health record integration.